Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

S100A9-clot not, bleed not

May 29, 2014 7:00 AM UTC

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing that risk.1

The new findings from U.S. researchers may hand a new indication to at least two companies-InflammatoRx Inc. and Active Biotech AB-developing inhibitors of this S100 protein to treat cancer, autoimmune diseases and inflammation...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article